Patients with perinatal HIV transitioning to adult care

Slides:



Advertisements
Similar presentations
UK Council of Research Repositories UKCoRR Launch - 21 st May 2007 University of Nottingham.
Advertisements

HYPnet Late presentation of vertically transmitted HIV infection in adolescence A Judd 1, R Ferrand 2,3, E Jungmann 2, C Foster 4, H Lyall 4, Brian Rice.
Key messages Antiretroviral therapy (ART) has transformed treatment of HIV infection The benefits of early diagnosis of HIV are well recognised - not offering.
BCIS Returns 1998 (Oct 1999) BCIS Audit Returns of Interventional Procedures 1998 Leicester, October 1999 Mark de Belder (Audit Secretary, BCIS) on behalf.
Is there a national shortage of Paediatric Radiologists?
Pdr36O review A service for students’ unions from.
BCIS Audit Returns of Interventional Procedures 2000 Mark de Belder BCIS UK National Audit Officer on behalf of Council of the British Cardiovascular Intervention.
Long-term virological outcome in HIV-infected children on ART in the UK/ Ireland Trinh Duong, Intira Jeannie Collins, Ali Judd, Katja Doerholt, Caroline.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2014* * Numbers are based on reports received rather than children seen to.
Protective HLA Class I alleles are associated with reduced immune activation in Primary HIV infection Elizabeth Hamlyn 1, Stephen Hickling 2, Abdel Babiker.
The UK Collaborative HIV Cohort (UK CHIC) Study
Proposed study on HIV and ageing As HIV mortality rates have dropped, an increasing proportion of individuals are living with HIV to older ages As HIV.
HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,
Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations.
The Prevalence of Darunavir Associated Mutations in PI-naive and PI- experienced HIV-1 Infected Children in the UK Katherine Boyd 1, A. Sarah Walker 1,
Great Britain Made by: Lyamkina Yulia. Satellite image of Great Britain.
(c) 2010 Vertual Ltd VERT - V irtual E nvironment for R adiotherapy T raining FDA Meeting - Session 2 - User Training Michael Meyer, Vertual Ltd President,
Long term follow up of the UK and Ireland paediatric cohort as teenagers transition to adult services Ali Judd, 1 Caroline Foster, 2 Caroline Sabin, 3.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2013* * Numbers are based on reports received rather than children seen to.
The UK HIV Drug Resistance Database: Development and use for national surveillance BACKGROUND Deenan Pillay 1 and Hannah Green 2 on behalf of the UK Collaborative.
Temporal patterns in the rate of transmitted resistance in the UK BACKGROUND Hannah Green 1, Anton Pozniak 2 and Kholoud Porter 1 on behalf of the UK Collaborative.
C Foster, A Judd, H Lyall, T Dunn, K Doerholt, P Tookey, D Gibb For Young people with perinatally acquired HIV: a Transitioning UK cohort.
Older and wiser: continued improvements in clinical outcome and highly active antiretroviral therapy (HAART) response in HIV-infected children in the UK.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2009* * Numbers are based on reports received rather than children seen to.
Characteristics and responses to ART in the CHIPS cohort, Katja Doerholt and Ali Judd on behalf of the Collaborative HIV Paediatric Study (CHIPS)
Catherine Kober Margaret Johnson Martin Fisher Caroline Sabin On behalf of UK-CHIC BHIVA/BASHH Manchester 2010 Non-uptake of HAART among patients with.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to May 2005.
Predicting NNRTI Resistance – do polymorphisms matter? Nicola E Mackie 1, Lucy Garvey 1, Anna Maria Geretti 2, Linda Harrison 3, Peter Tilston 4, Andrew.
Life expectancy of patients treated with ART in the UK: UK CHIC Study Margaret May University of Bristol, Department of Social Medicine, Bristol.
Switch to second-line therapy in the CHIPS cohort Dr Kate Lee MRC Clinical Trials Unit On behalf of the Collaborative HIV Paediatric Study (CHIPS) Steering.
To overdose or underdose? The question for Kaletra in children in the UK/Irish CHIPS cohort AS Walker 1, KL Boyd 1, Menson E 2, K Butler 3, P Tookey 4,
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2010* * Numbers are based on reports received rather than children seen to.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The United Kingdom provides excellent access and quality of.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2006* *Numbers are based on reports received rather than children seen to.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2012* * Numbers are based on reports received rather than children seen to.
CONCLUSIONS  Mortality and hospital admission rates continued to decline since the introduction of HAART in 1997  Viral load suppression 12 months after.
H Payne 1, K Donegan 2, I Okike 1, DM Gibb 2, K Doerholt 1, PT Heath 1 1. St Georges’ Healthcare NHS Trust 2. Clinical Trials Unit, Medical Research Council.
Review of the INIS nurse co-ordinator role Proposed INIS nurse support structure Jeanette Cousins INIS Study Nurse.
1 HIV Group, Medical Research Council Clinical Trials Unit, London, UK; 2 Department of Clinical Virology, Manchester Royal Infirmary, Manchester, UK.
22 February 2016 GRASP (Gonococcal Resistance to Antimicrobials Surveillance Programme) Catherine Ison Sexually Transmitted Bacteria Reference Laboratory.
Morbidity, mortality, and response to treatment in HIV-infected children in the UK & Ireland : a prospective cohort study Katja Doerholt, A Judd,
Exposure and response to highly active antiretroviral therapy (HAART) in ART naïve children in the UK and Ireland Judd A. 1, Lee K.J. 1, Duong T. 1, Walker.
Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4.
Mental health diagnoses in HIV infected young people: a HIV in Young People Network audit Dr Ellen Dwyer 1 Dr Caroline Foster 2 Dr Katia Prime 3 1 Croydon.
1 Wide disparity in switch to second-line therapy in HIV infected children CHIPS Kate Lee MRC Clinical Trials Unit On behalf of the Collaborative HIV Paediatric.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to June 2015* * Numbers are based on reports received rather than children seen to.
Seroprevalence and vaccination of measles, varicella and rubella in adolescents with vertically acquired HIV infection: a multicentre audit Elgalib A 1,2,
Malignancies in Young People Sophie Herbert, Alison Barbour, Eva Jungmann, Caroline Foster on behalf of the HIV Young Persons Network (HYPNET)
Neurocognitive function in perinatally HIV- infected young people and HIV-negative siblings in England Kate Sturgeon, Ali Judd, Aimie Nunn, Diane Melvin,
Specialist Pharmacy Service
National Haemglobinopathy Registry Manchester UK Forum Meeting
Valuing Individuals - Transforming Participation
Earlier treatment and lower mortality in infants Initiating ART at
Katja Doerholt on behalf of CHIPS NSHPC HYPNET CHIC
To overdose or underdose
Institutional Strategic Objectives Performance
People living with HIV can inform design of cure research: an online international survey Julie Fox.
Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda
1UCL, London, UK; 2Barts Health NHS Trust
Oesophago-Gastric Surgical Quality Improvement Alliance (OG-SQILL)
MHEALTH to Improve Health: Effectiveness of a weekly text messaging intervention to improve ART adherence and HIV Viral Load: WelTel OAKTREE. M.C.M. Murray1,2,3,
Professor Chris Whitty CB FMedSci Chief Scientific Adviser
Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2
Mortality and cause of death among HIV patients in London in 2016
Volume 2, Issue 12, Pages e530-e539 (December 2015)
11.University of Glasgow 12. University of Sheffield 13.Durham University 14. University of Birmingham 15. University of Southampton 16. University of.
Collaborative HIV Paediatric Study
Volume 5, Issue 6, Pages e301-e308 (June 2018)
Institutional Strategic Objectives Performance
National Oesophago-Gastric Cancer Audit
Presentation transcript:

Patients with perinatal HIV transitioning to adult care in the UK jeannie.collins@ucl.ac.uk Intira Jeannie Collins1, Francesca Parrott1, Caroline Sabin2, Teresa Hill2, Sophie Jose2 and Ali Judd1 on behalf of the Collaborative HIV Paediatric Study (CHIPS) Steering Committee and the UK Collaborative HIV Cohort Study (UK CHIC) P_82 1MRC Clinical Trials Unit at University College London, UK; 2 Research Department of Infection and Population Health, University College London, UK Introduction Due to improved survival for patients with perinatal HIV, adolescents are now transitioning from paediatric to adult care. There are few published data on clinical outcomes post-transfer. We used linked data from CHIPS and UK CHIC cohorts to describe mortality, antiretroviral treatment (ART), CD4 and viral load status pre- and post-transfer and to model CD4 change over the transition period. Methods The Collaborative HIV Paediatric Study (CHIPS): a multi-centre national cohort study of all children aged<16 years at diagnosis of HIV in UK/Ireland. A mixed effects model was fitted (allowing for multiple measures per person) to predict CD4 over time, adjusting for: Demographic characteristics (sex, ethnicity, born abroad) The UK Collaborative HIV Cohort Study (UK CHIC): a multi-centre cohort of HIV positive adults aged ≥16 years attending a collaborating adult clinic, represents approx. one-third of the national adult HIV population. Nadir CD4 cell count in paediatric care Age at transfer out of paediatric care, change of hospital at transfer Viral load <400c/mL (time-updated) within 6 months of the CD4 measurement Patients followed in CHIPS and aged ≥13 years by end of 2013 were matched with adults in UK CHIC. Time before/after transfer (modelled as a linear spline with one knot at transfer, time=0) Key outcomes in paediatric vs adult care were compared: (i) Proportion on ART; (ii) median CD4 count (iii) proportion with CD4<200 cells/mm3 in 24 months pre/post transfer and (iv) proportion with two consecutive VL>400 copies/mL while on ART for ≥6 months in 24 months pre/post transfer A priori interactions included were time from transfer with both age at transfer and change of hospital. Interactions of time with other variables were included if p<0.05. Results Of 1215 CHPS patients aged≥13 years, 271 (22%) were matched to UK CHIC, of whom 229 (85%) were documented in CHIPS as transferred to adult care, 25 (9.2%) were lost to follow-up in paediatric care and 17 (6.3%) were reported as still in paediatric care (due to reporting delay or being in the transition process). Median age of transfer out of paediatric care was 17 years and median duration of adult care follow up was 2.9 years (Table 1). For the key outcomes in paediatric vs adult care (Table 2): the proportion on ART increased from 74% to 84%, respectively median CD4 count was similar among those on ART, the proportion with VL>400 was similar. Predictors of CD4 over time CD4 was generally stable pre-transfer and declined after transfer to adult care (p=0.017) (Table 3). Pre-transfer CD4 slope was worse among females (vs males) and better for those with viral load suppression (Figure). There was a small but significant effect of worse slope with higher nadir CD4. The CD4 slope post transfer was better among females, and with some evidence of improved slope with older age at transfer (p=0.051). There was no effect of ethnicity or being born abroad on CD4 pre- or post-transfer. Change of hospitals at transfer had no effect on CD4 post-transfer. Table 1: Patient characteristics, N=271 Characteristic n (%) / median [IQR] Female 146 (53%) Perinatal HIV infection 237 (96%) Black ethnicity 213 (80%) Born abroad 163 (61%) Ever AIDS diagnosis* 86 (32%) Age at transfer out of paediatric care (years) 17 [16,18] Age at last follow up in adult care (years) 20 [19,23] Duration of paediatric care follow up (years) 11.8 [6.6,15.5] Duration of adult care follow up (years) 2.9 [1.5,5.9] Gap between paediatric & adult care (months)** 2.4 [1.0,4.4] Duration of total follow up (years) 15.4 [10.6,19.3] Note: *77 had first AIDS event in paediatric care. **17 had gaps between care >12 months Table 2: Comparing key outcomes in paediatric and adult care Outcome Paediatric care Adult care p-value n (%) / median [IQR] On ART at last follow up, N=271 200 (74%) 228 (84%) 0.001 Median CD4 count in 12 months pre/post transfer, N=189 456 [286,660] 450 [271,669] 0.37 CD4<200 at least once in 24 months pre/post transfer, N=195 61 (31%) 76 (39%) 0.01 Two consecutive VL>400 for those on ART for at least 6 months in 24 months pre/post transfer, N=181 91 (50%) 1.00 Table 3: Predictors of CD4 over time pre and post transfer, N=262 Predictors Coefficient 95% CI P-value Main effects Time before transition (per 1 year closer to transfer) 0.3 -8.9 , 9.6 0.94 Time after transition (per 1 year after transfer) -91.4 -166.7 , -16.2 0.017 Female -75.8 -122.3 , -29.4 0.001 Black ethnicity -26.5 -81.8 , 28.9 0.35 Born abroad -12.0 -57.4 , 33.5 0.61 Nadir CD4 cell count (per 10 unit increase) 6.5 5.0 , 8.0 <0.001 Viral suppression (time-updated)* Non-suppressed Suppressed <400 cps/mL Missing Ref 165.8 9.0 153.2 , 178.4 -56.3 , 74.3 0.79 Interactions with time before transition -15.6 -25.5 , -5.7 0.002 Nadir CD4 cell count (per 10 unit increase) -0.5 -0.74 , -0.2 6.0 -17.2 2.4 , 9.7 -32.1 , -2.2 0.024 Interactions with time after transition 21.7 10.0 , 33.5 Age at transfer out of paediatric care 4.2 -0.0 , 8.5 0.051 Changed hospital at transfer 8.0 -2.2 , 18.3 0.13 Figure: The effect of sex and time updated viral suppression on CD4 slopes over time for an example patient with the following characteristics: Black ethnicity, born in the UK, nadir CD4 of 207 cells/mm3, transferred to adult care at 17.5 yrs (sample means), no hospital change at transfer Conclusion This is the first analysis to match perinatally HIV infected adolescents followed in the CHIPS national cohort with the UK CHIC adult cohort, with follow-up data post-transfer to adult care. The proportion of patients on ART increased after transfer, although there was no change in the median CD4 count or the proportion with confirmed viremia on ART. After adjustment for other variables, CD4 appears to be relatively stable prior to transfer and decreases post-transfer. Some characteristics were protective of CD4 decline: females, older age at transfer and being virologically suppressed were associated with better CD4 slopes post transfer. Collaborative HIV Paediatric Study (CHIPS): CHIPS is funded by the NHS (London Specialised Commissioning Group) and has received additional support from Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Roche, Abbott, and Gilead Sciences. Participate hospitals: Republic of Ireland: Our Lady's Children’s Hospital Crumlin, Dublin: K Butler, A Walsh. UK: Birmingham Heartlands Hospital, Birmingham: S Scott, Y Vaughan, S Welch; Blackpool Victoria Hospital, Blackpool: N Laycock; Bristol Royal Hospital for Children, Bristol: J Bernatoniene, A Finn, L Hutchison; Calderdale Royal Hospital, Halifax: G Sharpe; Central Middlesex Hospital, London: A Williams; Chelsea and Westminster Hospital, London: EGH Lyall, P Seery; Coventry & Warwickshire University Hospital, Coventry: P Lewis, K Miles; Derbyshire Children’s Hospital, Derby: B Subramaniam; Derriford Hospital, Plymouth: L Hutchinson, P Ward; Ealing Hospital, Middlesex: K Sloper; Eastbourne District General Hospital, Eastbourne: G Gopal; Glasgow Royal Hospital for Sick Children, Glasgow: C Doherty, R Hague, V Price; Great Ormond St Hospital for Children, London: H Bundy, M Clapson, J Flynn, DM Gibb, N Klein, V Novelli, D Shingadia; Halliwell Children’s Centre, Bolton: P Ainsley-Walker; Harrogate District Hospital, Harrogate: P Tovey; Homerton University Hospital, London: D Gurtin; Huddersfield Royal Infirmary, Huddersfield: JP Garside; James Cook Hospital, Middlesbrough: A Fall; John Radcliffe Hospital, Oxford: D Porter, S Segal; King's College Hospital, London: C Ball, S Hawkins; Leeds General Infirmary, Leeds: P Chetcuti, M Dowie; Leicester Royal Infirmary, Leicester: S Bandi, A McCabe; Luton and Dunstable Hospital, Luton: M Eisenhut; Mayday University Hospital, Croydon: J Handforth; Milton Keynes General Hospital, Milton Keynes: PK Roy; Newcastle General Hospital, Newcastle: T Flood, A Pickering; Newham General Hospital, London: S Liebeschuetz; Norfolk & Norwich Hospital, Norwich: C Kavanagh; North Manchester General Hospital, Manchester: C Murphy, K Rowson, T Tan; North Middlesex Hospital, London: J Daniels, Y Lees; Northampton General Hospital, Northampton: E Kerr, F Thompson; Northwick Park Hospital Middlesex; M Le Provost, A Williams; Nottingham City Hospital, Nottingham: L Cliffe, A Smyth, S Stafford; Queen Alexandra Hospital, Portsmouth: A Freeman; Raigmore Hospital, Inverness: T Reddy; Royal Alexandra Hospital, Brighton: K Fidler; Royal Belfast Hospital for Sick Children, Belfast: S Christie; Royal Berkshire Hospital, Reading: A Gordon; Royal Children’s Hospital, Aberdeen: D Rogahn; Royal Cornwall Hospital, Truro: S Harris, L Hutchinson; Royal Devon and Exeter Hospital, Exeter: A Collinson, L Hutchinson; Royal Edinburgh Hospital for Sick Children, Edinburgh: L Jones, B Offerman; Royal Free Hospital, London: V Van Someren; Royal Liverpool Children’s Hospital, Liverpool: C Benson, A Riordan; Royal London Hospital, London: A Riddell; Royal Preston Hospital, Preston: R O’Connor; Salisbury District General Hospital, Salisbury: N Brown; Sheffield Children's Hospital, Sheffield: L Ibberson, F Shackley; Southampton General Hospital, Southampton: SN Faust, J Hancock; St George's Hospital, London: K Doerholt, S Donaghy, K Prime, M Sharland, S Storey; St Luke’s Hospital, Bradford: S Gorman; St Mary’s Hospital, London: EGH Lyall, C Monrose, P Seery, G Tudor-Williams, S Walters; St Thomas’ Hospital (Evelina Children’s Hospital), London: R Cross, E Menson; Torbay Hospital, Torquay: J Broomhall, L Hutchinson; University Hospital Lewisham, London: D Scott, J Stroobant; University Hospital of North Staffordshire, Stoke On Trent: A Bridgwood, P McMaster; University Hospital of Wales, Cardiff: J Evans, T Gardiner; Wexham Park, Slough: R Jones; Whipps Cross Hospital, London: K Gardiner; Steering Committee: Hermione Lyall, Karina Butler, Intira Jeannie Collins, Katja Doerholt, Caroline Foster, Di Gibb, Lynda Harper, Ali Judd, Nigel Klein, Esse Menson, Andrew Riordan, Delane Shingadia, Gareth Tudor-Williams, Pat Tookey, Steve Welch. MRC Clinical Trials Unit: IJ Collins, C Cook, DM Gibb, A Judd, L Harper, F Parrott, A Tostevin, D Dobson. United Kingdom Collaborative HIV Cohort (UK CHIC): UK CHIC Steering Committee: Jonathan Ainsworth, Jane Anderson, Abdel Babiker, Valerie Delpech, David Dunn, Philippa Easterbrook, Martin Fisher, Brian Gazzard (Chair), Richard Gilson, Mark Gompels, Teresa Hill, Margaret Johnson, Clifford Leen, Fabiola Martin, Chloe Orkin, Andrew Phillips, Deenan Pillay, Kholoud Porter, Caroline Sabin, Achim Schwenk, John Walsh. Central co-ordination: Research Department of Infection & Population Health, UCL, London (T Hill, S Huntington, S Jose, A Phillips, C Sabin, A Thornton); Medical Research Council Clinical Trials Unit (MRC CTU), London (D Dunn, A Glabay). Participating centres: Barts and The London NHS Trust, London (C Orkin, J Lynch, J Hand, C de Souza); Brighton and Sussex University Hospitals NHS Trust (M Fisher, N Perry, S Tilbury, D Churchill); Chelsea and Westminster NHS Trust, London (B Gazzard, M Nelson, M Waxman, D Asboe, S Mandalia); Public Health England, London (V Delpech); Homerton University Hospital NHS Trust, London (J Anderson, S Munshi, D Awosika); King’s College Hospital, London (F Post, H Korat, C Taylor, Z Gleisner, F Ibrahim, L Campbell); UCL Medical School and The Mortimer Market Centre, London (R Gilson, N Brima, I Williams); North Bristol NHS Trust (M Gompels, S Allen); North Middlesex University Hospital NHS Trust, London (A Schwenk, J Ainsworth, C Wood, S Miller); Royal Free NHS Trust and Department of Infection & Population Health, UCL, London (M Johnson, M Youle, F Lampe, C Smith, A Phillips, R Tsintas, C Chaloner, S Hutchinson); Imperial College Healthcare NHS Trust, London (J Walsh, N Mackie, A Winston, J Weber, F Ramzan); The Lothian University Hospitals NHS Trust, Edinburgh (C Leen, A Wilson); University of Leicester NHS Trust (A Palfreeman, A Moore, L Fox); South Tees Hospitals NHS Foundation Trust (D Chadwick, K Baillie); Woolwich NHS Trust (S Kegg, P Main); Coventry NHS Trust (S Allan); St. George’s NHS Trust (P Hay, M Dhillon); York (F Martin, S Douglas); The Royal Wolverhampton Hospitals NHS Trust (A Tariq, H Spencer, R Jones); Chertsey, Ashford and St Peter’s Hospitals NHS Foundation Trust (J Pritchard, S Cumming, C Atkinson); UK CHIC is funded by the UK Medical Research Council (Grant numbers G0000199, G0600337, G0900274 and M004236). The views expressed in this poster are those of the researchers and not necessarily those of the Medical Research Council. Acknowledgements